Figure 1From: Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: final results of a noninterventional studyCHANGE patient disposition. VEGFR-TKI, vascular endothelial growth factor receptor–tyrosine kinase inhibitor. aMore than one reason per patient. bAdverse event and death were reasons for discontinuation for four patients.Back to article page